GH Research PLC (NASDAQ:GHRS - Get Free Report)'s stock price rose 2.2% on Friday . The company traded as high as $8.76 and last traded at $8.28. Approximately 36,299 shares traded hands during trading, a decline of 54% from the average daily volume of 79,613 shares. The stock had previously closed at $8.10.
Analyst Ratings Changes
A number of research analysts have issued reports on the stock. JMP Securities reissued a "market outperform" rating and set a $39.00 target price on shares of GH Research in a research note on Wednesday, September 4th. HC Wainwright reissued a "buy" rating and set a $40.00 target price on shares of GH Research in a research note on Thursday, September 5th.
Read Our Latest Report on GH Research
GH Research Stock Up 0.6 %
The firm's 50 day moving average is $8.02 and its 200 day moving average is $10.53. The firm has a market capitalization of $424.04 million, a price-to-earnings ratio of -12.16 and a beta of 0.79.
GH Research (NASDAQ:GHRS - Get Free Report) last released its quarterly earnings data on Tuesday, September 3rd. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.03. On average, sell-side analysts predict that GH Research PLC will post -0.85 earnings per share for the current year.
Institutional Trading of GH Research
An institutional investor recently raised its position in GH Research stock. Lynx1 Capital Management LP raised its stake in GH Research PLC (NASDAQ:GHRS - Free Report) by 19.8% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,966,726 shares of the company's stock after purchasing an additional 656,163 shares during the period. GH Research makes up approximately 16.7% of Lynx1 Capital Management LP's holdings, making the stock its 3rd biggest position. Lynx1 Capital Management LP owned 7.62% of GH Research worth $46,252,000 as of its most recent SEC filing. Institutional investors and hedge funds own 56.90% of the company's stock.
GH Research Company Profile
(
Get Free Report)
GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).
Featured Stories
Before you consider GH Research, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GH Research wasn't on the list.
While GH Research currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
